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Abstract
The aim of these studies was to develop a novel 2’-behenoyl-paclitaxel (C22-PX) conjugate
nanoparticle (NP) formulation for the treatment of metastatic breast cancer. A lipophilic paclitaxel
derivative C22-PX was synthesized and incorporated into lipid-based NPs. Free C22-PX and its
NP formulation were evaluated in a series of in-vitro and in-vivo studies. The results demonstrated
that C22-PX NPs were much better tolerated and had significantly higher plasma and tumor AUCs
compared to Taxol at the maximum tolerated dose (MTD) in a subcutaneous 4T1 mouse
mammary carcinoma model. These benefits resulted in significantly improved antitumor efficacy
with the NP-based formulation.
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1. Introduction
Paclitaxel (PX) is one of the most effective chemotherapeutic anticancer drugs and is mainly
used to treat lung, ovarian, and breast cancer [1]. Due to its low water solubility, it is
formulated in a mixture of 50:50% (v/v) polyoxyethylated castor oil (Cremophor EL) and
dehydrated ethanol under the trademark “Taxol”. However, Cremophor EL is known to be
associated with serious side effects, such as hypersensitivity [2]. In addition, PX is known as
a substrate of P-glycoprotein (P-gp), which could actively pump PX out of the cells and
induce resistance [3]. To overcome these problems, several strategies have been applied,
mainly including modified “Cremophor-free” formulations [4–7] and/or structure
modification of the drug (e.g. PX analogs and prodrugs) [8–10].
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In recent years a great deal of research has been reported to formulate PX into different
nanosystems, such as o/w emulsions [4], micelles [5], liposomes [6], and solid lipid
nanoparticles [7]. These formulations have shown some benefits compared to Taxol both in-
vitro and in-vivo, however, in most cases the solubilization capacity of PX in these
formulations was limited and PX was released rapidly from the formulation. Furthermore,
most of the formulations lack mechanisms to overcome P-gp-mediated drug resistance.
Abraxane, a PX albumin-bound nanoparticle (NP) formulation with the particle size of ~130
nm, was approved by the FDA in 2005 for the treatment of metastatic breast cancer. Due to
the elimination of Cremophor EL and ethanol, this formulation demonstrates some
advantages in terms of reduced toxicity compared to Taxol. In a phase III clinical trial,
Abraxane demonstrated the improved response rates compared to Taxol in the treatment of
metastatic breast cancer as a first-line therapy [11]. However, in this phase III study,
Abraxane failed to show a statistically significant enhanced median survival compared to
Taxol (p = 0.374); therefore, whether Abraxane could improve survival is still unclear.
To potentially better target tumors and to address overcome P-gp-mediated drug resistance,
our laboratory has developed a new technology to engineer stable oil-filled lipid-based PX
BTM (Brij 78 and TPGS as the surfactants, and Miglyol 812 as the oil phase) NPs from oil-
in-water microemulsion precursors [12]. The loading capacity of the drug was up to 8%
(drug/oil, w/w), and only 50% of the drug was released in PBS after 72 h. This PX BTM NP
system has shown significantly greater anticancer efficacy in nude mice bearing resistant
NCI/ADR-RES tumors compared to Taxol. The mechanisms of PX BTM NPs to overcome
P-gp-mediated drug resistance were also investigated and shown to be due to P-gp inhibition
and ATP depletion [13].
To further improve the lipophilicity of PX and facilitate its retention in the lipid core,
modification of PX to a fatty acid-PX derivative is a potential approach. To date, many PX
derivatives have been reported to increase its water solubility [10, 14–16], or oppositely, to
enhance its lipophicility in order to entrap more drug into lipid-based formulations [17–20].
The most advanced fatty acid-PX derivative is docosahexaenoic acid-PX (DHA-PX) which
is currently in phase III clinical trials [19, 21–23]. DHA is linked to PX through an ester
bond on its C-2’ position. The DHA-PX conjugate does not have microtubule assembly
activity and is presumably non-toxic. The conjugate converts to active PX when metabolized
by esterases in the body. The conjugate was shown to prolong exposure of PX and reduce its
peak blood concentration, which allowed for 4.4-fold higher maximum tolerated dose
(MTD) of DHA-PX as compared to Taxol in mice. In an M109 subcutaneous lung tumor
mouse model, DHA-PX completely eliminated measurable tumors while PX did not result in
even partial tumor regression at its MTD [19]. However, there are some issues associated
with this conjugate: 1) it is still formulated in Cremophor EL/Ethanol; and 2) it remains a P-
gp substrate [24]. In the current studies, a 2’-behenoyl-paclitaxel (C22-PX) conjugate was
synthesized and formulated into our modified BTM NPs. A series of in-vitro studies were
performed to compare C22-PX conjugate to PX. In-vivo MTD, antitumor efficacy, and
pharmacokinetic and biodistribution studies of C22-PX NPs and Taxol were also conducted
in a 4T1 subcutaneous mouse model.
2. Materials and methods
2.1 Materials
PX powder was purchased from LC Laboratories (Woburn, MA, USA). PX injection was
bought from Hospira Inc. (Lake Forest, IL, USA). Polyoxyl 20-stearyl ether (Brij 78) was
obtained from Uniqema (Wilmington, DE, USA). D-alpha tocopheryl polyethylene glycol
1000 succinate (TPGS) was generously provided by Eastman Chemical Co. (Kingsport, TN,
USA). Behenoyl chloride, anhydrous dichloromethane (DCM), and 4-
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dimethylaminopyridine (DMAP) were purchased from Sigma (St. Louis, MO, USA). The
tubulin polymerization assay kit was purchased from Cytoskeleton Inc. (Denver, CO, USA).
4T1 mouse mammary carcinoma cell line was obtained from ATCC (Manassas, VA, USA).
The cell line was cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA)
containing 10% fetal bovine serum (FBS) (ATCC, Manassas, VA, USA) and antibiotics at
37°C in 5% CO2 humidified atmosphere.
2.2 Synthesis and characterization of C22-PX
A flame-dried round-bottom flask was charged with PX (25 mg, 2.9 × 10−5 mol, 1 equiv)
and DMAP (7.2 mg, 5.8 × 10−5 mol, 2 equiv) in anhydrous DCM (3 ml) under argon. The
solution was stirred for 10 min at 0°C. Behenoyl chloride (11 mg, 3.1 × 10−5 mol, 1.05
equiv) was added, and the reaction mixture was stirred for 6 h at 0°C under argon. The
reaction was monitored by TLC (EtOAc:hexanes 3:1 v/v, Rf = 0.74) for completion. After
completion, the solvent was removed by rotary evaporation in-vacuo and the crude product
was dissolved in diethylether (10 ml) and washed with 5% HCl (3 × 10 ml), and finally with
brine (10 ml) to remove the salt byproducts. The organic phase was dried over anhydrous
sodium sulfate, and the solvent was evaporated in-vacuo. The final C22-PX conjugate (29.3
mg, 85%) was obtained by silica-packed column chromatography purification with the
solvent system of EtOAc:hexanes (3:1, v/v). 1H NMR (400 MHz, CDCl3): δ (ppm) = 0.81
(t, 3H, –CH3(CH2)20), 1.06 (s, 6H, – H16,17), 1.18 (m, 18H, –(CH2)7CH2CH3), 1.61 (s, 3H,
–H19), 1.72 (m, 2H, –H6), 1.80 (m, 2H, – H14), 1.87 (s, 3H, –H18), 2.15 (s, 6H, –H22,31),
2.38 (d, 1H, –H3), 3.41 (q, 2H, –H5,7), 3.74 (s, 1H, –OH7), 3.76 (s, 1H, –OH1), 4.14 (d, 1H,
–H20), 4.23 (d, 1H, –H20), 4,39 (t, 1H, –H13), 4.86 (d, 1H, –H2), 5.22 (s, 1H, –H10), 5.84 (d,
1H, –H2’), 6.81 (d, 1H, –H3’), 7.18–7.32 (m, 5H, –Ar-H33–37), 7.32-35 (m, 3H, Ar-H26–28),
7.44 (m, 3H, Ar-H8’–10’), 7.66 (d, 2H, –Ar-H7’,11’), 8.05 (d, 2H, –Ar-H25,29). 13C NMR
(100 MHz, CD3OD): δ (ppm) = 8.58 (–C19), 13.1 (–CH3(CH2)20), 13.8 (–C18), 19.8 (–C31),
21.1 (–C22), 21.7 (–(CH2)19CH2CH3), 23.7 (–C16,17), 25.8 (–(CH2)18CH2CH2C1”), 30.9 (–
CH3CH2CH2(CH2)18C1”), 32.8 (–C6), 34.5 (–C14), 42.1 (–C15), 44.6 (–C3), 51.8 (–C3’),
57.5 (–C8), 70.7 (–C13), 71.1 (–C7), 72.8 (–C2), 74.1 (–C10), 74.6 (–C20), 76.3 (–C6’), 78.2
(–C1), 80.1 (–C4), 83.4 (–C5), 125.5 (–C33,35,37), 126.1 (–C7’,11’), 127.4–128.2 (–C26,28, –
C34,36, –C8’,10’), 129.2 (–C24,25,29), 132.6 (–C27), 131.0 (–C9’), 131.8 (–C27), 132.6 (–C32),
136.0 (–C11), 141.8 (–C12), 166.1 (–C23), 167.1 (–C5’), 168.8 (–C21, –C30), 170.2 (–C1’),
171.5 (–C1”), 202.8 (–C9). Mass spectrometry analysis also provided evidence for successful
preparation of the C22-PX conjugate. The mass of the observed molecular ion clearly
corresponded to the Na+ adduct of the conjugate, with no observable lower molecular
weight fragments or starting material. Calc.: [M]+ m/z = 1176.47. Found LC-MS: [M + Na+]
= 1198.13.
2.3 Quantitative analysis of PX and C22-PX
The concentration of PX was determined by HPLC/MS/MS system. The HPLC system
comprised a Finnigan Surveyor Autosampler Plus and a Finnigan Surveyor MS Pump Plus
(Thermo Scientific). Chromatographic separations were achieved using a SunFire™ C18
column (2.1 × 30 mm, 3.5 µm particle size, Waters) at 25°C. The mobile phase consisted of
the mixtures of methanol (solvent A) and 0.1% formic acid in deionized water (solvent B).
The elution protocol consisted of a 55:45 ratio (v/v) of solvent A to solvent B for 0.5 min,
followed by a gradient starting at 70:30 (A to B, v/v) over 6 min and finishing at 55:45 (A to
B, v/v) over 8 min. The flow rate was 0.5 ml/min. Mass spectrometric analysis was
performed by Thermo Scientific TSQ Quantum Access with positive ionization. The
capillary temperature was set to 390°C, and the spray voltage was 4000V. M/z 876.3 →
308.0 for PX and m/z 830.0 → 549.0 for docetaxel were used for quantification of analytes.
Docetaxel was added as the internal standard. To quantify PX concentration in plasma
samples, solid phase extraction was applied before the LC/MS assay. A Waters Oasis® HLB
Ma et al. Page 3













cartridge (1 cc/10mg) was used and conditioned by 20% methanol in dichloromethane,
methanol and water, then the plasma samples were loaded on the cartridge and washed by
5% methanol and 55% methanol in water, respectively. The collection samples were then
eluted by 20% methanol in dichloromethane, after which the organic solvent was removed
by rotary evaporation and the resulting solid was dissolved in the mobile phase for LC/MS
analysis.
The concentration of C22-PX was determined by HPLC analysis using an Inertsil ODS-3
column (4.6 × 150 mm, 3 µm particle size, GL Sciences) at the wavelength of 230 nm. The
mobile phase was acetonitrile/water/isopropanol (35:5:60, v/v/v) with a flow rate of 1.0 ml/
min. For the plasma or tissue samples, C22-PX was extracted from the samples by single
extraction with methanol/acetonitrile (2:1, v/v). The mixtures were then centrifuged at
14,000 g for 5 min, and the supernatant was collected and analyzed by HPLC assay.
2.4 Solubility of PX and C22-PX in different Miglyols
Excess PX or C22-PX powder was added into Miglyol 808, 810, 812, or 818, respectively,
and stirred at room temperature for 24 h. The samples were subsequently centrifuged at
25°C at the speed of 14,000 g for 20 min. The supernatant was accurately weighed and
dissolved in methanol in a 50 ml volumetric flask. The concentration of PX or C22-PX in
the flask was determined by LC-MS or HPLC analysis, respectively.
2.5 Tubulin polymerization activity of PX and C22-PX
A tubulin polymerization assay kit was purchased from Cytoskeleton Inc. (Cat# BK006P).
The assay is based on the principle that the light scattered by microtubules is proportional to
the concentration of tubulin polymer [25, 26]. The standard (control) polymerization
reaction contains 100 µl of 3 mg/ml tubulin in 80 mM PIPES pH 6.9, 0.5 mM EGTA, 2 mM
MgCl2, 1 mM GTP, and 10% glycerol. The assay was conducted at 37°C and the tubulin
polymerization reaction was monitored by the change in absorbance at 340 nm with a
temperature controlled Synergy 2 Multi-Detection Microplate Reader (BioTek, Winooski,
VT, USA). C22-PX concentrations of 5, 10, and 20 µM were applied in the assay. PX (10
µM) was used as the positive control.
2.6 In-vitro cytotoxicity of PX and C22-PX
The cytotoxicity of C22-PX and PX in 4T1 mouse mammary carcinoma cells was
determined using a MTT (3-[4,5–dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide)
assay [27]. Briefly, the viability of 4T1 cells was determined by trypan blue staining (>95%
cell viability for experiments) and the cells were counted and seeded in 96-well plates at
5,000 cells/100 µl growth medium. The C22-PX concentrations of 100, 250, 500, 1,000,
5,000, 10,000, and 25,000 nM, and PX concentrations of 1, 10, 50, 100, 250, 1,000, and
5,000 nM, respectively, were applied and added to the plate (100 µl/well) at 37°C in 5%
CO2 for 48 h. The cells were then incubated with MTT stock solution (5 mg/ml in PBS; pH
7.4) at 37°C for another 4 h. Next, the medium was removed and the converted dye was
solubilized with the addition of DMSO. The absorbance was measured using a Synergy 2
Multi-Detection Microplate Reader at 570 nm, and the concentration of drug that inhibited
cell survival by 50% (IC50) was determined from cell survival plots.
2.7 Optimization and characterization of C22-PX NPs
Our laboratory has developed “nanotemplate engineering” technology to successfully
prepare PX BTM NPs with a particle size of 200 nm [12]. Since C22-PX is more lipophilic
and to some extent exhibits a surfactant property, the current C22-PX BTM NP formulations
were optimized by decreasing the amount of surfactants of Brij 78 and TPGS used in the
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previous BTM formulation. In brief, Miglyol 812, Brij 78 and TPGS were first weighed in a
glass vial, and the vial was then heated to 65°C to melt the oil and surfactants while stirring.
Next, C22-PX, dissolved in ethanol, was transferred to the vial and ethanol was removed by
nitrogen gas. Finally, preheated deionized water was added into the vial to form a NP
suspension via the microemulsion precursor. C22-PX micelles were prepared in the same
manner as the NP formulation but without the oil phase of Miglyol 812. The particle size of
the NPs was determined by photon correlation spectroscopy (PCS) using a Coulter N5 Plus
Sub-Micron Particle Sizer (Beckman Coulter, Miami, FL, USA) at a fixed angle of 90° and
a temperature of 25°C. The optimal NP formulation was defined as the one with a narrow
particle size distribution of less than 200 nm, high drug entrapment efficiency in NPs, and
physical stability upon storage at 4°C or room temperature. The % drug entrapped in the
NPs was determined by gel permeation chromatography (GPC) method. Briefly, the
prepared NPs were applied to a 15 cm Sepharose CL-4B packed GPC column (Sigma, St.
Louis, MO, USA) and eluted with PBS as the mobile phase. The NP fractions of 5–8 (1 ml
per fraction) were collected and the total amount of C22-PX in these fractions was
determined. The % entrapment was calculated as follows: % Entrapment = [(Mass of drug in
NPs in GPC factions 5–8) / (Total mass of drug used to prepare formulation)] × 100% (w/w)
2.8 Stability of various C22-PX formulations in PBS at 37°C
Different C22-PX formulations, including free C22-PX, C22-PX NPs, and C22-PX micelles
were incubated in PBS at 37°C in a water bath. At the scheduled time points of 1, 4, 10, 24,
48 h, respectively, samples were collected and the concentration of C22-PX was determined
by HPLC. Free PX was used as the control and the final concentrations of the drug in the
experiment were 10 µg/ml.
2.9 C22-PX conversion to PX in tumor homogenates
All animal procedures followed NIH guidelines and were performed under protocols
approved by The University of North Carolina Institutional Animal Care and Use
Committee. To test C22-PX conversion to the more active drug of PX, C22-PX and C22-PX
NPs were spiked into fresh 4T1 tumor homogenate at the concentration of 10 µg/g tumor
and incubated at 37°C in a water bath. To obtain 4T1 tumor homogenate, a total of ten
BALB/c female mice from Charles River Laboratories (Wilmington, MA, USA) were first
subcutaneously injected with 1 × 106 4T1 cells. When tumors reached a volume of 200–300
mm3, the mice were sacrificed and the tumors were removed. Next, the tumors were
homogenized by Omni Bead Ruptor 24 Homogenizer (Kennesaw, GA, USA). At
predetermined time points, ~40–50 mg of tumor homogenate was collected. The
concentrations of both C22-PX and PX converted from C22-PX or C22-PX NPs were then
determined by HPLC and LC-MS analysis, respectively.
2.10 Maximum tolerated dose (MTD) studies of C22-PX NPs
The MTD studies of Taxol, C22-PX NPs, and C22-PX micelles were conducted in 4T1
tumor-bearing mice. BALB/c female mice from Charles River Laboratories (Wilmington,
MA, USA) were subcutaneously injected with 1 × 106 4T1 cells in the right flank. When the
tumors reached sizes in the range of 50–150 mm3 (5 days after cell inoculation), the mice
were injected by tail vein with different formulations with the treatment schedule of Q4d ×
3. A total of 7 groups were used in the study (2–3 mice/group): 30 and 40 mg PX/kg of
Taxol, 135 and 180 mg PX/kg of C22-PX NPs, 90 and 120 mg PX/mg of C22-PX micelles,
and an untreated group as the control. Mice body weight change was closely monitored on a
daily basis for two weeks. The MTD was defined as the allowance of body weight loss less
than 15% at the highest dose, and neither mice death due to toxic effects nor any remarkable
changes in general signs observed during the study.
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2.11 Pharmacokinetic and biodistribution studies
The pharmacokinetic and biodistribution of Taxol and C22-PX NPs were studied in 4T1
tumor-bearing mice. Four- to six-week-old BALB/c female mice were subcutaneously
injected with 1 × 106 4T1 cells into the right flank. When tumor sizes reached 200–300
mm3, the mice were injected via tail vein with Taxol or C22-PX NPs as a single bolus. A
total of 2 independent studies were performed, one was at the same dose of 10 mg PX/kg,
and the other one was at their MTDs (25 mg PX/kg for Taxol, and 160 mg PX/kg for C22-
PX NPs). In each study, mice were sacrificed at predetermined time points (3 mice/time
point), and plasma, the tissues of tumor, kidney, lung, heart, liver, and spleen were
harvested. Tissues were flash-frozen in liquid nitrogen and stored at −80°C. Upon analysis,
the frozen tissues were homogenized by Omni Bead Ruptor 24 Homogenizer (Kennesaw,
GA, USA) and the drug was extracted by a mixture of methanol/acetonitrile (2:1, v/v)
(except for PX plasma samples, which were extracted by solid phase extraction method
described above). The plasma concentration versus time data of both Taxol and C22-PX
NPs were analyzed by noncompartmental analysis using WinNonlin (Version 5.3, Pharsight
Co., Mountain View, CA, USA).
2.12 In-vivo antitumor efficacy studies at MTD
In-vivo antitumor efficacy studies of Taxol, C22-PX NPs, and C22-PX micelles at MTD
were carried out in a 4T1 subcutaneous mouse model. Four- to six-week-old BALB/c female
mice from Charles River Laboratories were subcutaneously injected with 1 × 106 4T1 cells
on Day (−5), and injected via tail vein with different formulations starting from Day 0 with
the treatment schedule of Q4d × 4. Mice were divided into a total of 6 groups in the study
(9–10 mice/group): 25 mg PX/kg of Taxol, 25 and 160 mg PX/kg of C22-PX NPs, 25 and
100 mg PX/kg of C22-PX micelles, and an untreated group as the control. The mice weight
and tumor size were measured every other day during the study, and tumor volume was
calculated as: [½ × (tumor width)2 × (tumor length)]. All the mice were sacrificed on Day 18
and upon sacrifice all tumors were harvested and weighed.
2.13 Statistical analysis
Statistical comparisons were analyzed using unpaired Student’s t-test for two groups, and
one-way analysis of variance (ANOVA) for multiple groups (Prism, Version 5.01,
GraphPad Software Inc, La Jolla, CA, USA). Differences were considered statistically
significant if the p value was < 0.05.
3. Results
3.1 Synthesis and characterization of C22-PX
To increase the retention of PX in the lipid core of the lipid-based NPs, a novel fatty acid-
PX derivative of 2’-behenoyl-PX conjugate (C22-PX) was synthesized via the coupling of
2’-behenoyl to the C-2’ hydroxyl position of PX (Figure 1). The structure was confirmed
by 1H- and 13C-NMR, MS, TLC and HPLC analyses. The product yield was 85% and the
purity was >95% determined by HPLC analysis.
3.2 Solubility of PX and C22-PX in different Miglyols
The solubilities of PX and C22-PX in different Miglyols at room temperature were
determined. Due to the introduction of a long carbon chain (C22), the solubility of C22-PX
in Miglyols increased to 15–25-fold compared to that of PX (51–73 versus 3.2–3.5 µg/mg
Miglyol for C22-PX and PX, respectively) as shown in Figure 2. Among all the tested
Miglyols, the solubility of C22-PX in Miglyol 812 was the highest (72.5 ± 17.1 µg/mg
Miglyol). Therefore, Miglyol 812 was chosen as the oil phase for further C22-PX NP
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preparation. It should be noted that because all of the tested Miglyols are composed of
medium chain triglycerides (C6–C10), there was no significant solubility difference within
the Miglyols for both C22-PX (p = 0.1878) and PX (p = 0.5083).
3.3 Tubulin polymerization activity of PX and C22-PX
In general, under standard (control) reaction conditions the microtubule polymerization
curve has three phases: nucleation (Figure 3A-I), growth (Figure 3A-II), and steady state
(Figure 3A-III). The Vmax value (mOD/min) is used to determine the ability of a ligand (PX
or C22-PX) to stabilize tubulin since this value is the most sensitive indicator of tubulin/
ligand interaction.
As shown in Figure 3B, PX at the concentration of 10 µM eliminated the nucleation phase
and had the greatest Vmax value of 45.0 ± 3.6 mOD/min, while the standard control had the
lowest Vmax value of 25.3 ± 3.2 mOD/min. For C22-PX conjugate, the interaction between
C22-PX and tubulin was dose dependent and at lower concentrations of 5 and 10 µM, C22-
PX had no effect on tubulin polymerization (p > 0.05 compared to control); however, it had
some tubulin polymerization activity at higher concentration of 20 µM (p < 0.01 compared
to control). It should be noted that PX at 10 µM was much more active than C22-PX at 20
µM (p < 0.01).
3.4 In-vitro cytotoxicity of PX and C22-PX
In-vitro cytotoxicity studies of free C22-PX and PX were conducted in the 4T1 cell line. The
IC50 value C22-PX was about 8-fold higher than PX (282 ± 42 versus 38 ± 1 nM). The
results were expected and consistent with other reported 2’-fatty acid-PX conjugates [17, 20,
29] where the conjugates were much less toxic compared to PX since C-2’ hydroxyl group is
essential for PX cytotoxicity and microtubule assembly activity.
3.5 Optimization and characterization of C22-PX NPs
C22-PX NP formulations were engineered using a microemulsion precursor method
previously described by the Mumper group [27]. The C22-PX BTM NPs were optimized in
terms of drug entrapment in NPs, particle size and NP stability. Since C22-PX exhibits some
surfactant property due to the presence of both lipophilic and hydrophilic moieties within the
structure, C22-PX BTM NP formulations were optimized by decreasing the amount of
surfactants of Brij 78 and TPGS based on our previous PX BTM NPs. A total of four BTM
NP formulations (Formulations I–IV in Table 1) were investigated, and the particle sizes and
drug entrapment in NPs were determined. All formulations were acceptable in terms of
particle size except for Formulation I. As shown in Table 1, as the amount of surfactant
utilized decreased, the amount of drug retained in the NP fraction increased. This was
expected because the Miglyol and surfactants in the system competitively solubilize C22-
PX. Although Formulation IV led to the highest drug content in NP fractions, the NPs
precipitated within one week upon storage at 4°C. In contrast, Formulation III was much
more stable and its blank NPs were stable for at least 4 months upon storage even at room
temperature. Therefore, Formulation III was selected as the optimized C22-PX BTM
formulation.
Interestingly, although C22-PX NPs were monodisperse with low polydispersity indices by
photon correlation spectroscopy, two distinct particle size populations (100–200 nm and ~50
nm) were elucidated when C22-PX NPs were passed through a Sepharose CL-4B column
using PBS as the elution solvent (Figure 4A). As expected, drug content of C22-PX NPs in
NP fractions 5–8 was much higher than PX NPs, which is due to the more lipophilic
property of C22-PX conjugate (Figure 4B). Therefore, C22-PX micelles with particle size of
~50 nm were used as the control. C22-PX from C22-PX micelle formulation eluted in the
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later fractions 9–14, which confirmed the existence of a population of smaller size C22-PX
NPs after PBS elution (Figure 4C). It should be noted that for fractions 9–14 of C22-PX NPs
with particle size of ~50 nm, it is unknown whether they are micelles, smaller oil-filled NPs
or a combination of both.
3.6 Stability of various C22-PX formulations in PBS at 37°C
The in-vitro stability of free C22-PX, C22-PX NPs, and C22-PX micelles in PBS was
investigated. Free PX was used as the control. As shown in Figure 5A, free C22-PX
underwent degradation upon incubation in PBS at 37°C as a function of time and only ~30%
was retained after 48 h. It should be noted that the degradation behavior of C22-PX in PBS
was very similar to free PX. In contrast, C22-PX NP or micelle formulations were very
stable with no C22-PX degradation occurring within 48 h incubation in PBS, which
indicated that the NP or micelle formulations could protect C22-PX from chemical
degradation in PBS.
3.7 C22-PX conversion to PX in tumor homogenates
In-vitro C22-PX hydrolysis studies were performed in fresh 4T1 tumor homogenates at
37°C to test C22-PX conversion to the active form of PX. As shown in Figure 5B, a small
amount of PX was formed from either free C22-PX or C22-PX NPs within the first 10 h.
After 10 h, PX was gradually detected, and at 48 h the amount of PX derived from free C22-
PX or C22-PX NPs was 5–7% of the total C22-PX added. This suggested that a fraction of
PX could be converted from C22-PX or from its NP formulations in the tumors.
3.8 Maximum tolerated dose (MTD) studies of C22-PX NPs
MTD studies of Taxol, C22-PX NPs, and C22-PX micelles were conducted in 4T1 tumor-
bearing BALB/c mice with the treatment schedule of Q4d × 3. The results are summarized
in Table 2. The body weight loss in all groups was less than 6% throughout the whole study.
Due to toxicity, 2 of 2 mice that received 40 mg PX/kg Taxol died immediately upon the
first injection, and 1 out of 3 mice died after the second treatment with C22-PX NPs and
C22-PX micelles at the doses of 180 and 120 mg PX/kg, respectively. Therefore, the MTDs
of Taxol, C22-PX NPs, and C22-PX micelles were determined as 30–40, 135–180, 90–120
mg PX/kg, respectively. It was noted that all mice in the Taxol group at a dose of 30 mg PX/
kg lost consciousness immediately upon injection but recovered after several minutes,
whereas mice treated with NP and micelle formulations did not. On the basis of the results,
MTDs of 25, 160, and 100 mg PX/kg for Taxol, C22-PX NPs, and C22-PX micelles,
respectively, were chosen for subsequent in-vivo antitumor efficacy studies.
3.9 Pharmacokinetic and biodistribution studies
Pharmacokinetic and biodistribution studies of C22-PX NPs and Taxol at two dose levels of
10 mg PX/kg and their MTDs were conducted (Figures 6 and 7). As shown in Figures 6A,
7A and Table 3, PX concentration from Taxol dropped rapidly in plasma due to its short
half-life and its concentration was lower than the HPLC detection limit after 8 h and 48 h at
doses of 10 and 25 mg PX/kg, respectively. In contrast, the concentrations of C22-PX and
PX derived from C22-PX NPs declined much slower. The plasma AUCs of C22-PX from
C22-PX NPs were 22- and 186-fold greater than PX from Taxol at doses of 10 mg PX/kg
and MTD, respectively. The half-life of C22-PX from C22-PX NPs increased 8-fold (8.57 h
versus 1.09 h) compared to PX from Taxol at a dose of 10 mg PX/kg. The clearance rate and
volume distribution of C22-PX from C22-PX NPs in plasma were also significantly
decreased. All these results suggested that C22-PX NPs had a long circulation time and were
largely confined in the blood stream. The distributions of C22-PX from C22-PX NPs and
PX from Taxol in various tissues are summarized in Figures 6B, 6C, 7B and 7C. In general,
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PX concentration from Taxol decreased as a function of time and PX was widely distributed
into most tissues including liver, lung, kidney and heart. In contrast, C22-PX from C22-PX
NPs reached a maximal concentration between 1–4 h after intravenous administration in
most tissues, and C22-PX was mainly distributed in the liver and spleen. Importantly, tumor
AUCs of C22-PX from NP formulations were 2.6- and 24.4-fold higher than PX from Taxol
at doses of 10 mg PX/kg and MTD, respectively. Tumor AUC of PX derived from C22-PX
NPs was 1.5-fold greater than PX from Taxol at their MTDs (Figure 7D and Table 3).
3.10 In-vivo antitumor efficacy studies at MTD
In-vivo antitumor efficacy studies of Taxol, C22-PX NPs and C22-PX micelles at MTD
were evaluated in a 4T1 subcutaneous mouse model (Figure 8). Two dose levels of C22-PX
NPs and micelles were applied in the study: MTD of Taxol at 25 mg PX/kg, and their
unique MTDs as determined (160 mg PX/kg for C22-PX NPs and 100 mg PX/kg for C22-
PX micelles). Treatments with all formulations at any dose level were well tolerated by the
mice since their body weight was comparable to the untreated mice (Figure 8A), indicating
no induced toxicity by either NP or micelle formulations even at their MTDs. As expected,
the tumor growth rate of untreated group was the highest. The C22-PX NPs at MTD
exhibited significantly more potent in-vivo tumor inhibitory activities than other groups
starting from Day 6 (Figure 8B). It should be noted that both C22-PX NPs and C22-PX
micelles had similar antitumor activity with Taxol at the dose of 25 mg PX/kg, and the
increase from 25 to 100 mg PX/kg of C22-PX micelles did not further improve the
antitumor efficacy (p > 0.05). Results from tumor weight (Figure 8C) were consistent with
tumor size measurements, where tumors from the untreated mice were the largest and
heaviest, and tumors from mice treated with C22-PX NPs at MTD were the smallest and
statistically significant compared to all other groups (p < 0.05).
4. Discussion
PX is a very effective anticancer drug; however, due to its low water solubility and lack of
ionizable functional groups, a great deal of effort has been focused to synthesize more
water-soluble PX derivatives [15]. Alternatively, more lipophilic PX derivatives have been
developed for lipid-based formulations. PX derivatives are generally designed at the C-2’
position because the free hydroxyl group at this position is much more reactive than the C-7
hydroxyl group, and PX-ester based derivatives can be synthesized selectively at C-2’ group
of PX without protecting the C-7 hydroxyl group. To date, several synthesized 2’-fatty acid-
PX ester derivatives have been reported, such as 2’-linoleic acid-PX [30], 2’-
carbonylcholesterol-PX [20], 2’-oleate-PX [17], 2’-α-bromohexadecanoyl-PX [29], and
DHA-PX [19, 23], all of which showed some benefits compared to Taxol in-vitro and/or in-
vivo. For example, the lipophilic 2’-oleate-PX conjugate showed significantly greater AUC,
higher Cmax, and lower systemic clearance compared to PX formulated in Cremophor EL/
Ethanol in a rabbit model [17]. Perkins et al. synthesized 2’-α-bromohexadecanoyl-PX
conjugate and further incorporated it into lipid-coated particles termed “lipocores”. Their in-
vivo studies demonstrated that the lipocores were much less toxic than Taxol after i.p or i.v.
administration and were active in the ovarian carcinoma SCID mice model [29]. As
mentioned above, DHA-PX has also been investigated. In an M109 s.c. mouse model, the
tumor AUCs of PX from DHA-PX conjugate were 1.71- and 5.79-fold greater than Taxol
when i.v. injected into mice at equimolar and equitoxic doses, respectively [19]. However,
results from the most recent Phase III study to treat metastatic malignant melanoma were
disappointing where DHA-PX was not superior to dacarbazine in terms of overall survival,
and there were no significant differences between the two drugs in patient response rate,
duration of response, and time to progression on an every 3-week treatment schedule [22].
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In this study, a novel 2’-behenoyl-PX ester derivative (C22-PX) was successfully
synthesized and its structure was confirmed by 1H- and 13C-NMR, MS, TLC and HPLC
analyses. Since the C-2’ hydroxyl group is essential for PX cytotoxicity and microtubule
assembly activity, the C22-PX conjugate should be much less toxic compared to PX if it
does not convert to its more active form of PX. This was supported by 1) the tubulin
polymerization assay (Figure 3). PX could stabilize microtubule proteins at 10 µM, however,
C22-PX had no microtubule activity at this concentration but did have a dose dependent
ability to stabilize microtubules. The results were similar to DHA-PX and 2’-linoleic acid-
PX where both of the prodrugs were not able to assemble microtubule at the concentration
level of 10 µM [19, 30]; 2) in-vitro cytotoxicity studies in 4T1 cells showed that the
cytotoxicity of C22-PX was much lower than its parent PX (IC50: 282 ± 42 versus 38 ± 1
nM) after 48 h incubation in cell culture medium. These results were consistent with other
2’-fatty acid-PX prodrugs. For example, 2’-α-bromohexadecanoyl-PX, and 2’-diglycolate-
and succinate-PX produgs were 70- and 10–100-fold, respectively, less potent compared to
PX against human MCF-7 cells at a 72 h incubation time [18, 29]. DHA-PX was reported to
be cytotoxic at the µM concentration range, while PX was in nM range for a variety of
human tumor cell lines [19]. Similarly, the cytotoxicity of 2’-oleate-PX in lipid emulsions
was much lower than that of PX but with time dependent manner, where the IC50 values
were 5500, 500, 150, and 100 nM for 24, 48, 72, and 96 h incubation, respectively,
compared to an IC50 of 50 nM for Taxol at 48 h in HeLa cells [17]. The differences in the
IC50 between C22-PX conjugate and PX may be due to a slow hydrolysis rate of C22-PX to
release PX, which was supported by C22-PX hydrolysis in 4T1 tumor homogenates, where
only about 5–7% of C22-PX was converted to PX during 48 h incubation for both free C22-
PX and C22-PX NPs (Figure 5B). To provide faster hydrolysis rates, electron-withdrawing
substituents in the α-position of the fatty acid can be introduced. A 2’-α-
bromohexadecanoyl-PX has been synthesized and is currently under investigation in our
laboratory.
The C22-PX BTM NP formulations were engineered using a microemulsion precursor
method previously described by the Mumper group [27, 31]. Miglyol 812 was used as the oil
phase based on its highest solubilization capacity for C22-PX (Figure 2), and because C22-
PX solubility in the oil phase of Miglyol 812 increased 25-fold compared to PX (72.5 ± 17.1
versus 3.2 ± 0.1 µg/mg Miglyol), the drug entrapment in our lipid-based NPs improved
significantly which was confirmed by GPC. When C22-PX NP formulations passed through
a Sepharose CL-4B GPC column, 47% of the drug conjugate was retained in the 200 nm
NPs versus only 10% for previous PX NPs (Figure 4B), likely due to the more lipophilic
property of C22-PX. Interestingly, although C22-PX NPs showed a mono-distribution
profile with a low polydispersity index by photon correlation spectroscopy, two distinct
particle size populations were elucidated by the GPC method (Figure 4A). These results
were consistent with previous findings reported by Jay et al. on solid lipid NPs containing
stearyl alcohol where two distinct size populations were obtained following elution through
a GPC column [28]. Previously, an ultracentrifuge method was applied to determine the
drug entrapment efficiency and the results may be somehow misleading since drugs may
precipitate and aggregate during the ultracentrifugation process and/or may also bind to the
filter membrane. In contrast, the GPC method is more dynamic and presumably more
accurate in predicting the in-vivo fate of NPs.
The in-vitro stability of free C22-PX and C22-PX NPs was investigated at 37°C in PBS
(Figure 5A). Interestingly, C22-PX degraded in PBS over time and only ~30% of C22-PX
was retained after 48 h incubation. It was reported that PX hydrolyzes to its main
degradation products of baccatin III and V, 10-deacetylbaccatin III, and 7-epi-PX in PBS,
and its degradation kinetics was determined to be first order for the first 12 h [32]. In the
present studies, free PX was used as the control and the degradation behavior of C22-PX in
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PBS was found to be very similar to that of free PX. Therefore, it was hypothesized that
C22-PX and PX undergo similar degradation pathways in PBS. In contrast, both C22-PX NP
and micelle formulations were stable and no C22-PX degradation occurred during a 48 h
incubation in PBS, which indicated that the NP or micelle formulations could protect C22-
PX from degradation in PBS.
Since C22-PX BTM NPs were free of Cremophor EL and ethanol which are the solvents in
Taxol, the vehicle associated toxicity should be much less. In fact, this was confirmed by the
6-fold greater MTD of C22-PX NPs compared to Taxol (Table 2). The antitumor efficacy of
C22-PX NPs at MTD was then evaluated in a 4T1 s.c. mouse model with a Q4d × 4
treatment schedule. C22-PX NPs at MTD exhibited no toxicity based on the body weight
change which was comparable to the untreated mice (Figure 8A). More importantly, C22-
PX NPs demonstrated a significantly superior antitumor activity compared to Taxol and
C22-PX micelles at MTD (Figures 8B and 8C). To better understand the in-vivo behavior of
C22-PX NPs, a total of two pharmacokinetic and tissue biodistribution studies of C22-PX
NPs versus Taxol were conducted at doses of 10 mg PX/kg and MTD, respectively (Figures
6–7). PX concentration from Taxol declined very rapidly in plasma while C22-PX from
C22-PX NP formulations had much longer circulation time in blood, where the plasma
AUCs of C22-PX from C22-PX NPs were 22- and 186-fold greater than those of PX from
Taxol at doses of 10 mg PX/kg and MTD, respectively. The prolonged circulation time
would enable NP formulations to take full advantage of EPR effect thus more of the drug
would be expected to accumulate at the tumor site. This was confirmed by the fact that the
tumor AUCs of C22-PX from the NP formulations were 2.6- and 24.4-fold greater than that
of PX from Taxol at doses of 10 mg PX/kg and MTD, respectively. It should be noted that
the tumor AUC of PX derived from C22-PX NPs was 1.5-fold greater than PX from Taxol
at their MTDs. Taken together, there are at least three possible reasons for the enhanced
antitumor efficacy of C22-PX NPs at MTD: 1) the 6-fold increase in MTD allowed much
higher doses of the drug to be delivered to mice; 2) C22-PX NPs had a significantly
improved pharmacokinetic profile and prolonged circulation time in the blood, and much
higher drug accumulation in the tumor due to the EPR effect, based on the facts that the
plasma and tumor AUCs of C22-PX from C22-PX NPs were 186- and 24.4-fold greater than
PX from Taxol at MTD, respectively; and 3) Once C22-PX NPs reached the tumor site, PX
was converted and released from C22-PX in a sustained manner.
It should be noted that the BTM NPs were able to overcome P-gp mediated MDR both in-
vitro and in-vivo, and the mechanisms were investigated and included: 1) increase drug cell
uptake and retention; 2) inhibition of P-gp; and 3) transient depletion of ATP [13]. Since
resistance to PX remains a significant unmet problem, the ability of BTM NPs to address
this problem may be very promising. Unfortunately, the 4T1 murine cell line in this study is
not resistant [33]. However, the 4T1 cell line was very aggressive based on the facts that 1)
the tumor size of untreated mice reached ~1500 cm3 after 20–25 days of cell injection; 2)
the Q4d × 4 treatment with Taxol at MTD of 25 mg/kg did not show better antitumor
inhibition effect compared to untreated mice (Figure 8B). It is expected that C22-PX BTM
NPs would have much better antitumor efficacy if resistant and less aggressive mouse
models were to be utilized. In addition, EGFR targeted NPs could potentially be engineered
to further improve the anticancer efficacy and enhance the therapeutic index of PX.
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Synthesis of C22-PX conjugate via a one-step esterification reaction of PX and behenoyl
chloride. The synthesized C22-PX conjugate was confirmed by 1H- and 13C- NMR, MS,
TLC, and HPLC analyses.
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Solubility of C22-PX conjugate and PX in different Miglyols. Excess C22-PX and PX were
added into Miglyols and were kept stirred for 24 h at room temperature. The samples were
then centrifuged at 14,000 g for 20 min at 25°C. After that, the supernatant was collected,
accurately weighed, and dissolved in methanol in a 50 ml volumetric flask. The
concentrations of C22-PX and PX were determined by HPLC and LC-MS analysis,
respectively. Results are expressed as mean ± SD (n = 3).
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Tubulin polymerization assay of C22-PX conjugate. The standard (control) polymerization
reaction contains 100 µl of 3 mg/mL tubulin in 80 mM PIPES pH 6.9, 0.5 mM EGTA, 2
mM MgCl2, 1 mM GTP, and 10% glycerol. The assay was conducted at 37°C and the
tubulin polymerization was monitored by the change of the absorbance at 340 nm over a 60
min period (1 reading per min) with a temperature controlled Microplate Reader. C22-PX
concentrations of 5, 10, and 20 µM were applied in the assay. PX (10 µM) was used as the
positive control. (A) Tubulin polymerization curves of control, PX, and C22-PX. (B) Vmax
values of control, PX, and C22-PX. Data are presented as mean ± SD (n = 3). (** p < 0.01,
*** p < 0.001)
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Gel permeation chromatography elution profiles with a Sepharose CL-4B column. A total of
20 fractions were collected (1 ml/fraction) with the elution solvent of PBS. (A) Particle size
(♦) and intensity (■) of each fraction of C22-PX NPs. (B) % drug retention in various
fractions of PX NPs (■) and C22-PX NPs (□). Results are expressed as mean ± SD (n = 3).
(C) % C22-PX retention in each fraction of C22-PX NPs (■) or C22-PX micelles (○). %
drug retention was calculated as: [(mass of drug in each fraction) / (total mass of drug
loaded into the column)] × 100% (w/w)
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Various C22-PX formulations incubated in PBS and 4T1 tumor homogenates at 37°C in a
water bath. (A) Different C22-PX formulations incubated in PBS and at the predetermined
time points, samples were collected and the concentration of C22-PX were determined by
HPLC. Free PX was used as the control and the final concentrations of the drug in the
experiment were 10 µg/ml. (B) C22-PX and C22-PX NPs were spiked into fresh 4T1 tumor
homogenates at the concentration of 10 µg/g tumor and incubated at 37°C in a water bath. At
predetermined time points, ~40–50 mg of samples was taken out. The concentrations of both
C22-PX and PX converted from C22-PX or C22-PX NPs were determined by HPLC or LC-
MS analysis. Results are expressed as mean ± SD (n = 3).
Ma et al. Page 18














Pharmacokinetic and biodistribution studies of Taxol and C22-PX NPs in a 4T1 mammary
carcinoma mouse model at a dose of 10 mg PX equivalent per kg. BALB/c female mice (n =
3 per group) were s.c. injected with 1 × 106 4T1 cells and i.v. tail vein injected different
formulations when the tumors reached to 200–300 mm3. (A) Drug concentrations in mouse
plasma. (B) PX concentrations from Taxol. (C) C22-PX concentrations from C22-PX NPs.
(D) Drug concentrations in tumor. Data are presented as the mean ± SD.
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Pharmacokinetic and biodistribution studies of Taxol and C22-PX NPs in a 4T1 mammary
carcinoma mouse model at MTD. BALB/c female mice (n = 3 per group) were s.c. injected
with 1 × 106 4T1 cells and i.v. tail vein injected different formulations when the tumors
reached to 200–300 mm3. (A) Drug concentrations in mouse plasma. (B) PX concentrations
from Taxol. (C) C22-PX concentrations from C22-PX NPs. (D) Drug concentrations in
tumor. Data are presented as the mean ± SD.
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In-vivo antitumor efficacy studies of Taxol, C22-PX NPs, and C22-PX micelles in a 4T1
mammary carcinoma mouse model. BALB/c female mice (n = 9–10 per group) were s.c.
injected with 1 × 106 4T1 cells on Day (−5), and tail vein injected with different
formulations starting from Day 0 with the treatment schedule of Q4d × 4. The mice weight
and tumor sizes were measured every other day [tumor size was calculated as ½ × (width)2
× (length)]. All the mice were sacrificed on Day 18 and upon sacrifice the tumors of all the
mice were removed and weighed. (A) Mice weight. (B) Tumor size. (C) Tumor weight. Data
are presented as the mean ± SEM. (* p < 0.05, ** p < 0.01, compared to C22-PX NPs at the
dose of 160 mg/kg)
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